SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs Advisory Committee meeting on 12 July 2017 to review the CTL019 (tisagenlecleucel-T) Biologics License Application (BLA) filing in relapsed and refractory (r/r) paediatric and young adult patients with B-cell acute lymphoblastic leukaemia (ALL).
Novartis announced in March 2017 that the FDA accepted CTL019 for review and granted priority review status.
Oxford BioMedica is the sole manufacturer of the lentiviral vector expressing CTL019 for Novartis. As announced in October 2014, Oxford BioMedica will also receive undisclosed royalties on potential future sales of Novartis CAR-T products.
For further information, please contact: | |
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer | Tel: +44 (0)1865 783 000 |
| Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton | Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.
About FDA Advisory Committee meetings
FDA Advisory Committees consist of a panel of independent, external experts. The FDA convenes Advisory Committees to provide advice on scientific, technical and policy matters related to human and veterinary drugs, vaccines and other biological products, medical devices, and food. The FDA is not obligated to follow the advice of the committee.
